Project twelve months across three operating modes. Inputs: discipline, geography, current revenue, audience.
About this tool
The Creative Revenue Calculator projects a creative practice
across three operating postures over a twelve-month horizon. The
multipliers are midpoints drawn from published industry data:
retail contribution benchmarks (WGSN), compensation studies (BoF),
the NEA's artist earnings series, and RIAA published artist share
data. Geography adjustments reflect purchasing-power and market-size
differentials. The audience multiplier follows a diminishing-returns
curve consistent with observed conversion at scale.
The output is a planning tool, not a forecast. Every practice is
a special case. The calculator is useful for a first-pass comparison
between operating modes. For a specific opportunity assessment, the
Nonesuch division best suited to your discipline is the next step.
Questions
What do the three scenarios represent?
Solo is the creative working alone, retaining full control and full operational risk. Signed is a single partner across distribution and rights. Multi-deal is a cross-discipline catalog under representation, with three or more concurrent revenue streams.
Where do the multipliers come from?
Published industry reporting: WGSN retail benchmarks, BoF compensation studies, NEA artist earnings data, RIAA artist-share disclosures, and observed catalog math from the Nonesuch Index. All values are conservative midpoints.
Why does geography matter?
Currency, market size, and pricing elasticity vary materially across regions. The geographic adjustment reflects a practice operating inside the stated market, not exporting into it.
What if I have zero current revenue?
The calculator assumes a non-zero base. If you are pre-revenue, set the value to the smallest monthly figure you reasonably expect in the first 90 days and treat the output as a Q2 through Q4 projection.
Is this a quote?
No. The calculator is a planning tool. Any engagement with a Nonesuch division is scoped separately, in writing, after intake.